Qiagen (NYSE:QGEN – Get Rating) has earned an average rating of “Hold” from the nine research firms that are covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $54.65.
Several analysts have recently commented on QGEN shares. William Blair restated a “market perform” rating on shares of Qiagen in a research note on Tuesday, November 8th. Morgan Stanley started coverage on Qiagen in a research note on Tuesday, October 18th. They issued an “equal weight” rating for the company. StockNews.com started coverage on Qiagen in a research note on Wednesday, October 12th. They issued a “buy” rating for the company. Berenberg Bank raised their target price on Qiagen from €53.91 ($55.01) to €54.60 ($55.71) in a research note on Friday, November 11th. Finally, Oddo Bhf cut shares of Qiagen from an “outperform” rating to a “neutral” rating in a research report on Monday, October 10th.
Hedge Funds Weigh In On Qiagen
Several hedge funds have recently modified their holdings of the company. Massachusetts Financial Services Co. MA lifted its position in shares of Qiagen by 0.3% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 20,508,125 shares of the company’s stock worth $1,004,898,000 after buying an additional 51,481 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Qiagen by 1.7% during the 3rd quarter. Vanguard Group Inc. now owns 8,274,403 shares of the company’s stock worth $341,568,000 after buying an additional 135,640 shares in the last quarter. BlackRock Inc. lifted its position in shares of Qiagen by 0.4% during the 3rd quarter. BlackRock Inc. now owns 7,346,030 shares of the company’s stock worth $303,245,000 after buying an additional 28,497 shares in the last quarter. Pendal Group Ltd lifted its position in shares of Qiagen by 63.9% during the 3rd quarter. Pendal Group Ltd now owns 5,258,339 shares of the company’s stock worth $217,065,000 after buying an additional 2,049,960 shares in the last quarter. Finally, Amundi increased its stake in shares of Qiagen by 10.5% during the 2nd quarter. Amundi now owns 3,865,333 shares of the company’s stock worth $177,846,000 after purchasing an additional 367,066 shares during the last quarter. Institutional investors own 55.65% of the company’s stock.
Qiagen Stock Performance
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
- Get a free copy of the StockNews.com research report on Qiagen (QGEN)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Want to Get a 10% Dividend Yield, Look Here
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.